MX376122B - Composiciones de plinabulina. - Google Patents

Composiciones de plinabulina.

Info

Publication number
MX376122B
MX376122B MX2018000451A MX2018000451A MX376122B MX 376122 B MX376122 B MX 376122B MX 2018000451 A MX2018000451 A MX 2018000451A MX 2018000451 A MX2018000451 A MX 2018000451A MX 376122 B MX376122 B MX 376122B
Authority
MX
Mexico
Prior art keywords
plinabulin
compositions
polymorphs
preparation
disclosed
Prior art date
Application number
MX2018000451A
Other languages
English (en)
Other versions
MX2018000451A (es
Inventor
Aniruddh Singh
Lan Huang
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57757489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX376122(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of MX2018000451A publication Critical patent/MX2018000451A/es
Publication of MX376122B publication Critical patent/MX376122B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/004—Fractional crystallisation; Fractionating or rectifying columns
    • B01D9/0045—Washing of crystals, e.g. in wash columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D2009/0086—Processes or apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen en la presente polimorfos de plinabulina, composiciones, su uso y preparación como agentes terapéuticos. En particular, algunas modalidades se relacionan con plinabulina monohidratada en una forma cristalina.
MX2018000451A 2015-07-13 2016-07-11 Composiciones de plinabulina. MX376122B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562191990P 2015-07-13 2015-07-13
PCT/US2016/041773 WO2017011399A1 (en) 2015-07-13 2016-07-11 Plinabulin compositions

Publications (2)

Publication Number Publication Date
MX2018000451A MX2018000451A (es) 2018-05-07
MX376122B true MX376122B (es) 2025-03-07

Family

ID=57757489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000451A MX376122B (es) 2015-07-13 2016-07-11 Composiciones de plinabulina.

Country Status (21)

Country Link
US (5) US10155748B2 (es)
EP (2) EP3334726B1 (es)
JP (2) JP6969848B2 (es)
KR (1) KR102680823B1 (es)
CN (3) CN109516981B (es)
AU (2) AU2016291708B2 (es)
BR (1) BR112018000229A2 (es)
CA (1) CA2991059C (es)
CL (1) CL2018000098A1 (es)
CO (1) CO2018000350A2 (es)
DK (1) DK3334726T3 (es)
EC (1) ECSP18010481A (es)
ES (1) ES2910035T3 (es)
IL (1) IL256559B2 (es)
MX (1) MX376122B (es)
MY (1) MY181892A (es)
NZ (1) NZ778077A (es)
PE (1) PE20180528A1 (es)
PH (1) PH12018500071A1 (es)
SG (1) SG10202108194XA (es)
WO (1) WO2017011399A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265091A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
BR112018074990A2 (pt) 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
WO2018028420A1 (zh) * 2016-08-12 2018-02-15 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备纯化方法和应用
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
US11434225B2 (en) 2017-08-03 2022-09-06 Pliva Hrvatska D.O.O. Salts and solid state forms of plinabulin
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
KR20240144396A (ko) * 2022-02-10 2024-10-02 비욘드스프링 파마수티컬스, 인코포레이티드. 안정한 플리나불린 제제와 이의 조제 및 사용 방법
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (es) 1973-05-11 1975-01-30
GB2090830B (en) 1980-12-18 1984-09-26 Wellcome Found Formyl ether derivatives
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
ES2096215T3 (es) 1992-10-01 1997-03-01 Wellcome Found Tucaresol como agente inmunopotenciador.
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
DE69842004D1 (de) 1997-11-21 2010-12-30 Purdue Neuroscience Co Substituierte 2-aminoacetamide und anwendung davon
HUP0101329A3 (en) 1998-01-29 2002-07-29 Aventis Pharmaceuticals Inc Co Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
CN1142909C (zh) 1998-03-26 2004-03-24 盐野义制药株式会社 具有抗病毒活性的吲哚衍生物
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
JP4810043B2 (ja) 2000-01-18 2011-11-09 ネリアス・ファーマシュティカルズ・インコーポレーテッド 細胞分裂阻害剤及びその製造方法
WO2001070663A2 (en) 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
HUP0302358A3 (en) 2000-05-09 2007-09-28 Adpharma Piperazinedione compounds and use of them for producing pharmaceutical compositions
EP1345938A1 (en) 2000-12-28 2003-09-24 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
RU2321396C2 (ru) 2002-05-17 2008-04-10 Авентис Фарма С.А. Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DK1529044T5 (da) * 2002-08-02 2008-04-21 Nereus Pharmaceuticals Inc Dehydrophenylahistiner og analoger deraf og syntesen af dehydrophenylahistiner og analoger deraf
CN101633655B (zh) * 2002-08-02 2014-04-30 大连万春药业有限公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CN1934101B (zh) * 2004-02-04 2011-10-12 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
JP2007520565A (ja) * 2004-02-04 2007-07-26 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成
HRP20160757T1 (hr) 2004-04-19 2016-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Postupak za proizvodnju polimorfnog oblika i od klopidogrel-vodik-sulfata
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
JP4559240B2 (ja) 2005-01-13 2010-10-06 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム、無線基地局、無線回線制御局及び電力制御方法
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN101657213B (zh) 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
CN101678078B (zh) 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2558568T3 (es) 2008-01-08 2016-02-05 Bristol-Myers Squibb Company Combinación de anticuerpo anti-CTLA4 con agentes moduladores de la tubulina para el tratamiento de enfermedades proliferativas
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
CA2749786A1 (en) 2009-01-16 2010-07-22 Jason Benjamin Bock New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
ES2543280T3 (es) 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
WO2011034954A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. Treatment of cancer
US20110274723A1 (en) 2009-10-23 2011-11-10 Mannkind Corporation Cancer immunotherapy and method of treatment
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
WO2011109625A1 (en) 2010-03-03 2011-09-09 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2012074904A2 (en) 2010-11-29 2012-06-07 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
AU2012344676A1 (en) 2011-11-28 2014-06-19 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
KR102165348B1 (ko) 2012-05-09 2020-10-14 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
HK1216231A1 (zh) 2013-06-03 2016-10-28 Novartis Ag Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
ES2902665T3 (es) 2013-10-11 2022-03-29 Beyondspring Inc Tratamiento del cáncer con combinación de plinabulina y taxano
US20150273033A1 (en) 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
CN106232831B (zh) 2013-11-06 2021-02-26 美国卫生和人力服务部 通过表达谱分析对淋巴瘤类型进行亚型分类的方法
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
IL286282B2 (en) 2015-02-12 2023-10-01 Beyondspring Pharmaceuticals Inc Use of palinabolin in combination with immune checkpoint inhibitors
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
EP3265091A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
BR112018074990A2 (pt) 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
BR112019018880A2 (pt) 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN112105363A (zh) 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
US20210161888A1 (en) 2018-06-01 2021-06-03 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
JP2021534183A (ja) 2018-08-16 2021-12-09 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫応答を刺激するための方法及び組成物

Also Published As

Publication number Publication date
SG10202108194XA (en) 2021-09-29
US12024501B2 (en) 2024-07-02
CL2018000098A1 (es) 2018-07-20
KR102680823B1 (ko) 2024-07-03
PH12018500071B1 (en) 2018-07-23
EP3334726B1 (en) 2022-03-16
NZ778077A (en) 2024-11-29
CN113735834A (zh) 2021-12-03
KR20180027563A (ko) 2018-03-14
CA2991059C (en) 2024-01-16
BR112018000229A2 (pt) 2018-09-04
HK1251559A1 (zh) 2019-02-01
US20180194749A1 (en) 2018-07-12
US20240425485A1 (en) 2024-12-26
DK3334726T3 (da) 2022-05-16
US20200277280A1 (en) 2020-09-03
US10155748B2 (en) 2018-12-18
MY181892A (en) 2021-01-12
PH12018500071A1 (en) 2018-07-23
EP3334726A1 (en) 2018-06-20
EP3334726A4 (en) 2019-04-17
CN109516981A (zh) 2019-03-26
US20220169635A1 (en) 2022-06-02
AU2021201784B2 (en) 2022-12-01
WO2017011399A1 (en) 2017-01-19
CN113735834B (zh) 2023-06-13
IL256559B2 (en) 2023-07-01
CO2018000350A2 (es) 2018-06-12
AU2021201784A1 (en) 2021-04-15
CN108026075B (zh) 2021-06-29
ECSP18010481A (es) 2018-04-30
AU2016291708A1 (en) 2018-02-01
JP2021181497A (ja) 2021-11-25
AU2016291708B2 (en) 2020-12-24
MX2018000451A (es) 2018-05-07
EP4011878A1 (en) 2022-06-15
US11254657B2 (en) 2022-02-22
JP6969848B2 (ja) 2021-11-24
CN108026075A (zh) 2018-05-11
JP2018520178A (ja) 2018-07-26
NZ739083A (en) 2024-11-29
US10550104B2 (en) 2020-02-04
ES2910035T3 (es) 2022-05-11
US20190106410A1 (en) 2019-04-11
CA2991059A1 (en) 2017-01-19
IL256559A (en) 2018-02-28
IL256559B1 (en) 2023-03-01
PE20180528A1 (es) 2018-03-19
CN109516981B (zh) 2019-10-22

Similar Documents

Publication Publication Date Title
MX376122B (es) Composiciones de plinabulina.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX388170B (es) Polimorfos de selinexor
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
MX2017008444A (es) Picolinamidas como fungicidas.
PH12015502118A1 (en) Pyridin-4-yl derivatives
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
PH12018501166B1 (en) Concentrated gibberellin solution formulations
DOP2016000062A (es) Derivados de indol-urea de glucopiranosil sustituido y su uso como inhibidores de sglt
UA117233C2 (uk) Композиція з тривалим вивільненням лоразепаму
EA201691191A1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона

Legal Events

Date Code Title Description
FG Grant or registration